AKAO Achaogen, Inc.

22.29
+0  (1%)
Previous Close 22.17
Open 22.40
Price To book 7.40
Market Cap 797.56M
Shares 35,781,000
Volume 430,622
Short Ratio 3.59
Av. Daily Volume 972,082

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2Q 2017
C-Scape
Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - EPIC trial
Complicated urinary tract infections (cUTI)
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)

Latest News

  1. Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  2. Achaogen, Inc. breached its 50 day moving average in a Bearish Manner : AKAO-US : April 11, 2017
  3. Achaogen to Present at Needham & Company’s 16th Annual Healthcare Conference
  4. Harry Boxer’s five technology and biotechnology stocks to watch
  5. Achaogen Announces Data on Epidemiological Trends of Carbapenem-Resistant Enterobacteriaceae at SHEA Spring 2017 Conference
  6. Achaogen, Inc. breached its 50 day moving average in a Bullish Manner : AKAO-US : March 28, 2017
  7. ETFs with exposure to Achaogen, Inc. : March 27, 2017
  8. Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
  9. Achaogen, Inc. :AKAO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  10. Achaogen, Inc. :AKAO-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  11. Why The Rubicon Project, Titan International, and Achaogen Slumped Today
  12. Achaogen reports 4Q loss
  13. Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  14. Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2016 Financial Results on March 14, 2017
  15. Achaogen to Present at the Cowen and Company 37th Annual Health Care Conference
  16. Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company's R&D Day
  17. Achaogen Announces New Employment Inducement Grants
  18. Achaogen Adds Janet Dorling as Chief Commercial Officer
  19. Achaogen Announces Leadership Promotions
  20. Achaogen Announces Achievement of a Key Milestone in Developing a Plazomicin Assay to Support Therapeutic Drug Management (TDM)